Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 16599 | 580 | 45.5 | 90% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 151 | 22214 | IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | CANC VACCINE DEV PROGRAM | Address | 26 | 80% | 3% | 16 |
| 2 | CANC SECT | Address | 14 | 42% | 5% | 27 |
| 3 | ONCOANTIGENS | Author keyword | 14 | 100% | 1% | 7 |
| 4 | CANC IMMUNOL IMMUNOTHER Y | Address | 12 | 35% | 5% | 28 |
| 5 | HER 2 NEU PEPTIDES | Author keyword | 12 | 86% | 1% | 6 |
| 6 | JOYCE MURTHA BREAST CARE | Address | 11 | 100% | 1% | 6 |
| 7 | CANCER IMMUNOPREVENTION | Author keyword | 6 | 80% | 1% | 4 |
| 8 | TUMOR VACCINE GRP | Address | 6 | 25% | 3% | 20 |
| 9 | IMMUNOL BIOL METASTASIS | Address | 4 | 67% | 1% | 4 |
| 10 | BIOTECHNOL SATELLITE UNIT BOLOGNA | Address | 4 | 75% | 1% | 3 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | ONCOANTIGENS | 14 | 100% | 1% | 7 | Search ONCOANTIGENS | Search ONCOANTIGENS |
| 2 | HER 2 NEU PEPTIDES | 12 | 86% | 1% | 6 | Search HER+2+NEU+PEPTIDES | Search HER+2+NEU+PEPTIDES |
| 3 | CANCER IMMUNOPREVENTION | 6 | 80% | 1% | 4 | Search CANCER+IMMUNOPREVENTION | Search CANCER+IMMUNOPREVENTION |
| 4 | IMMUNOPREVENTION | 3 | 37% | 1% | 7 | Search IMMUNOPREVENTION | Search IMMUNOPREVENTION |
| 5 | E75 | 2 | 26% | 1% | 8 | Search E75 | Search E75 |
| 6 | DISCONTINUOUS B CELL EPITOPE | 2 | 67% | 0% | 2 | Search DISCONTINUOUS+B+CELL+EPITOPE | Search DISCONTINUOUS+B+CELL+EPITOPE |
| 7 | MMTVNEU | 2 | 67% | 0% | 2 | Search MMTVNEU | Search MMTVNEU |
| 8 | TUMOR PREVENTION | 2 | 26% | 1% | 6 | Search TUMOR+PREVENTION | Search TUMOR+PREVENTION |
| 9 | AE37 | 1 | 100% | 0% | 2 | Search AE37 | Search AE37 |
| 10 | AE37 VACCINE | 1 | 100% | 0% | 2 | Search AE37+VACCINE | Search AE37+VACCINE |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | GROUP STUDY I 01 | 33 | 72% | 4% | 26 |
| 2 | E75 VACCINE | 27 | 78% | 3% | 18 |
| 3 | TRANSGENIC BALB C MICE | 26 | 67% | 4% | 24 |
| 4 | HER 2 NEU TRANSGENIC MICE | 21 | 35% | 8% | 49 |
| 5 | HER2 NEU E75 VACCINE | 15 | 77% | 2% | 10 |
| 6 | HUMAN ERBB 2 | 15 | 88% | 1% | 7 |
| 7 | ANTI ERBB 2 ANTIBODY | 14 | 100% | 1% | 7 |
| 8 | IMMUNOPREVENTION | 13 | 58% | 3% | 15 |
| 9 | HER2 NEU DERIVED PEPTIDE | 12 | 53% | 3% | 16 |
| 10 | HER 2 NEU PROTOONCOGENE | 12 | 43% | 4% | 21 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives | 2013 | 18 | 56 | 63% |
| Anti-HER2 vaccines: new prospects for breast cancer therapy | 2010 | 38 | 116 | 51% |
| Vaccines for tumour prevention | 2006 | 130 | 100 | 37% |
| HER-2/neu as a target for cancer vaccines | 2010 | 21 | 111 | 50% |
| Tumor antigen-specific T helper cells in cancer immunity and immunotherapy | 2005 | 250 | 60 | 18% |
| The GP2 peptide: A HER2/neu-based breast cancer vaccine | 2012 | 9 | 30 | 57% |
| Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines | 2011 | 9 | 25 | 52% |
| Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines | 2013 | 8 | 109 | 32% |
| A New Era in Anticancer Peptide Vaccines | 2010 | 32 | 60 | 22% |
| DNA vaccination against oncoantigens A promise | 2012 | 7 | 65 | 48% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CANC VACCINE DEV PROGRAM | 26 | 80% | 2.8% | 16 |
| 2 | CANC SECT | 14 | 42% | 4.7% | 27 |
| 3 | CANC IMMUNOL IMMUNOTHER Y | 12 | 35% | 4.8% | 28 |
| 4 | JOYCE MURTHA BREAST CARE | 11 | 100% | 1.0% | 6 |
| 5 | TUMOR VACCINE GRP | 6 | 25% | 3.4% | 20 |
| 6 | IMMUNOL BIOL METASTASIS | 4 | 67% | 0.7% | 4 |
| 7 | BIOTECHNOL SATELLITE UNIT BOLOGNA | 4 | 75% | 0.5% | 3 |
| 8 | TRANSLAT MED WOMENS HLTH | 3 | 22% | 1.9% | 11 |
| 9 | INTER CANC GIORGIO PRODI | 3 | 50% | 0.7% | 4 |
| 10 | RENA ROWEN BREAST | 3 | 60% | 0.5% | 3 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000220256 | 5T4//TUMOR IMMUNOL BIOL//5T4 ONCOFETAL ANTIGEN |
| 2 | 0.0000148358 | CCDC134//TUMOR IMMUN TOLERANCE SECT//ANTIGEN SPECIFIC CTL FUNCTION |
| 3 | 0.0000147082 | CANCER TESTIS ANTIGEN//CANCER TESTIS ANTIGENS//NY ESO 1 |
| 4 | 0.0000144683 | C ERBB 2//HER 2 NEU//P185 |
| 5 | 0.0000131691 | CANC VACCINE DEV//INNOVAT CANC THER Y//PERSONALIZED PEPTIDE VACCINE |
| 6 | 0.0000114760 | ANTIANGIOGENIC CANCER VACCINE//CELL PROTEOMIC FOOTPRINTING//HER1 VACCINE |
| 7 | 0.0000112870 | BELAGENPUMATUCEL L//SRL172//PA MSHA |
| 8 | 0.0000102338 | FOXP3//TUMOR INFILTRATING LYMPHOCYTES//INTEGRAT CANC IMMUNOL |
| 9 | 0.0000087781 | TRASTUZUMAB//LAPATINIB//PERTUZUMAB |
| 10 | 0.0000087529 | DENDRITIC CELLS//DENDRITIC CELL//TUMOR LYSATE |